Prostate Cancer

At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, discussed the recommendations issued for the early detection of metastatic prostate cancer using next-generation imaging.

Novartis announced that its investigational targeted radioligand therapy 177Lu-PSMA-617 demonstrated statistically significant improvements in overall and radiographic progression-free survival versus standard-of-care therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

The use of next-generation imaging, like PSMA PET, has been shown to be superior compared with conventional imaging and may become a homestay in prostate cancer care in the future.

These data in Nature Communications found that Black men may derive survival benefits from immunotherapy treatment.

The trial investigated the association of bone metastatic burden and metastasis location with overall survival and failure-free survival, suggesting the potential for these data to predict survival benefits.

Data from Radiology found early positive results regarding the treatment of intermediate-risk prostate cancer with MRI-guided focused ultrasound ablation.

A study published in JAMA Oncology found that, of 6 tested systemic treatment options, abiraterone acetate and apalutamide were the likeliest to improve overall survival when combined with ADT for patients with metastatic castration-sensitive prostate cancer.

More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.

Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.

Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.

The potential to identify occult prostate cancer and accurately characterize disease burden was observed with the novel prostate specific membrane antigen (PSMA)–targeted radiopharmaceutical for PET imaging technique.

Darolutamide still has a favorable safety profile with prolonged treatment among patients with nonmetastatic castration-resistant prostate cancer.

For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy, abiraterone acetate and prednisone plus the addition of apalutamide reduced the risk of radiographic progression or death by 30%.

Antitumor activity and a tolerable safety profile were observed for VERU-111, a novel tubulin inhibitor, to treat patients with metastatic castration-resistant prostate cancer who previously failed an androgen receptor–targeting agent.

ONCOLOGY® sat down with Leonard G. Gomella, MD, professor and chair of Thomas Jefferson University Hospital’s Department of Urology and clinical director of the Sidney Kimmel Cancer Center Network, to discuss 10 years of breakthroughs for patients with prostate cancer and the hope that continued research will fully transform prostate cancer from a deadly disease into a chronic, manageable condition.

A study of capivasertib plus chemotherapy did show a statistically significant extension in overall survival despite not reaching the primary end point of progression-free survival, suggesting a need for prospective validation studies to determine the reasoning behind the observed differences in these results.

CancerNetwork®’s podcast features Justin Gregg, MD, lead author of a study investigating the Mediterranean diet and how it impacts men with localized prostate cancer.

To evaluate the association between radiation facility case volume and OS among men with lymph node–positive prostate cancer who receive external beam radiation therapy, this cohort study assessed men diagnosed with T1N1M0 to T4N1M0 disease treated with curative-intent radiotherapy and androgen deprivation therapy.

In response to the drug’s developer, the FDA added overall survival and other end point data to the label of darolutamide for its indication for treating patients with nonmetastatic castration-resistant prostate cancer who are receiving standard androgen-deprivation therapy.

“These findings highlight the dynamic interplay between both providers and their patients as well as between the latter’s [health literacy] and [shared decision making] that should inform the creation and promulgation of [shared decision making] guidelines, specifically when considering patients with low [health literacy],” wrote David-Dan Nguyen, MPH, and colleagues.

Treatment with olaparib versus physician’s choice of standard therapy led to a significantly longer duration of overall survival in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1/2 or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.

“In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer,” the study authors wrote.

Though these collective findings demonstrate that genetic predisposition to increased weight is protective against breast and prostate cancer, further research is still necessary to work out exactly how this protection is provided, especially in breast cancer.